A randomized phase II study to assess the effect of adjuvant immunotherapy using α-GalCer-pulsed dendritic cells in the patients with completely resected stage II–IIIA non-small cell lung cancer: study protocol for a randomized controlled trial

BACKGROUND: As the toxicity associated with the α-GalCer-pulsed dendritic cell (DC) therapy could be considered to be negligible, its addition to postoperative adjuvant chemotherapy would be expected to greatly improve the therapeutic effect, and could result in prolonged survival. The aim of the pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Saka, Hideo, Kitagawa, Chiyoe, Ichinose, Yukito, Takenoyama, Mitsuhiro, Ibata, Hidenori, Kato, Tatsuo, Takami, Koji, Yamashita, Motohiro, Maeda, Tadashi, Takeo, Sadanori, Ueda, Hitoshi, Okabayashi, Kan, Nagashima, Seiji, Oka, Tadayuki, Kouso, Hidenori, Fukuyama, Seiichi, Yoshimoto, Kentaro, Shimokawa, Mototsugu, Saito, Akiko M., Ito, Suminobu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5603008/
https://www.ncbi.nlm.nih.gov/pubmed/28915900
http://dx.doi.org/10.1186/s13063-017-2103-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5603008/
https://www.ncbi.nlm.nih.gov/pubmed/28915900
http://dx.doi.org/10.1186/s13063-017-2103-4

Ejemplares similares